A Phase I Study to Assess the Safety of HIV and Hep C Vaccines Candidates When Given Separately or in Combination

Size: px
Start display at page:

Download "A Phase I Study to Assess the Safety of HIV and Hep C Vaccines Candidates When Given Separately or in Combination"

Transcription

1 A Phase I Study to Assess the Safety of HIV and Hep C Vaccines Candidates When Given Separately or in Combination Sponsor: University of Oxford EudraCT No.: REC: South Central Oxford A REC Ref. No.: 14/SC/0195 PARTICIPANT INFORMATION LEAFLET Thank you for showing interest in this study. Before you decide to take part, it is important that we explain why this research is being done and what it will involve. You should be aged years, Hepatitis C (Hep C) and HIV-negative, and healthy. Women who are interested in participating should not be pregnant or intending to become pregnant during the study period. Participating in this trial does not mean that you will become immune to HIV or Hepatitis C. If you take part, we will advise you on how to protect yourself against HIV and Hepatitis C infection. Please take time to read the following information carefully and discuss it with friends, relatives or your GP if you wish. Please ask us if there is anything that is not clear or if you would like more information. Why is this study being done? Hep C and HIV are both common infections. By the end of 2010, there were 2.3 million people in Europe living with HIV, and over half of these people were co-infected with the Hep C virus. Vaccination is the most effective way to prevent many infectious diseases, but developing effective vaccines against HIV and Hep C is extremely challenging. One of the main reasons for this is the enormous variation in Hep C and HIV types around the world. This is caused by the extraordinary ability of the viruses to change their genes. Oxford University researchers have developed vaccine candidates for both HIV and Hep C and have tested these in people. All of the vaccines to be given during this study been shown to be safe and able to induce an immune response. However, the aim of the study is to find out whether vaccines for HIV Page 1 of 10

2 and Hep C can, when given together, induce immune responses that are similar in strength to when each vaccine is given separately. Many licensed vaccines are given as combinations, such diphtheria, tetanus, whooping cough and polio. The advantage of combined vaccinations for many diseases is that fewer clinic visits are needed and there is less chance of any of the vaccine components being missed. Because many people in the world are at risk of both HIV and Hep C it would be an advantage to prevent both infections with as few immunisations as possible. What are the vaccines being tested in this study? The vaccines being tested in this study each consist of two parts. The first part is known as a carrier (also called a vector ). The carriers are harmless viruses: a chimpanzee adenovirus called ChAd or AdCh, which is similar to human common cold viruses, and a type of smallpox vaccine called modified vaccinia virus Ankara (MVA), neither of which can cause disease in people. The second part of each vaccine contains segments of the genes of the HIV or Hep C virus. The HIV and Hep C components of the vaccines are completely synthetic and do not contain live HIV or Hep C, therefore they cannot give people Hep C or HIV infection, or AIDS. The vaccines are called AdCh3NSmut1 ( Hep C1 ), MVA-NSmut ( Hep C2 ), ChAd63.HIVconsv ( HIV 1 ) and MVA.HIVconsv ( HIV 2 ). What would I be vaccinated with? During this study, 32 individuals will be allocated into three groups. The first group of 8 individuals will receive two Hep C vaccines by injection the first will be Hep C1 and will be followed eight weeks later by Hep C2. The second group of 8 individuals will receive two HIV injections the first will be HIV 1 and will be followed eight weeks later by HIV 2. The third group of 16 individuals will receive four injections for HIV and HCV together. The first two injections will be given at the same time, one of HIV 1 and one of Hep C 1. This will be followed 8 weeks later by two more injections, one of HIV 2 and one of Hep C 2. Do I have to take part? It is entirely your decision as to whether or not to take part. If you do decide to take part you will be asked to sign a consent form. After you have done so, you are still free to withdraw at any time and without giving a reason. How often do I need to attend? You will be asked to attend for 12 study visits over a period of 8 months. Page 2 of 10

3 What do I have to do if I agree to take part? Screening Visit On the first visit (screening visit) the study doctor or nurse will discuss the study in detail with you to make sure that you fully understand what the study is about and what is involved if you decide to take part, and that you are happy to give written consent to take part in the study. If you decide to take part we will give you a copy of the consent form that you have signed which you can keep for your records together with this information sheet. We will give you an appointment schedule for the study visits. If appropriate, we will ask you to ensure that you use effective contraception throughout the study. We will ask you questions about your health and any medications you are taking and give you a physical examination. During the physical examination, we will measure your weight and vital signs, including pulse, blood pressure and temperature. We will also ask questions to ensure that you are not at risk of HIV and Hep C infection. A blood sample and a urine sample will be taken in order to confirm that you are eligible to take part. The urine sample will be used to test for protein and glucose, as well for pregnancy if you are female. The blood sample will be used for tests including for HIV, Hep C and Hep B infections. These tests will be explained to you in detail. If we identify any reason that would prevent you from taking part in this study this will be discussed with you. If a minor abnormality is noted on a screening blood test, a repeat test might be required to verify it. We will see you within two weeks to give you the results and discuss whether you might still be eligible for vaccination. We will ask you to refrain from participating in other clinical trials at the same time. In addition we will ask your permission to register you on the TOPS database ( which is a confidential national database of healthy volunteers and when they take part in studies, to minimise the risks that can come from over-volunteering. You will be asked you provide your National Insurance number if you are a UK citizen or passport number and country of origin if you are not a UK citizen. Vaccination Visits On the vaccination visits you will be given an injection into the muscle over the shoulder region of one or both arms, depending on which group you have been assigned to. We will monitor you for between 30 minutes and 1 hour at the clinic to ensure that there is no serious reaction to the vaccine(s). Page 3 of 10

4 Before going home, you will be given a diary card and telephone number(s) to call the doctor or nurse in case you have any side effects or concerns about the vaccine. During the next three days you will be asked to keep a daily record of your temperature and any flu - like symptoms that you might experience. A doctor or nurse will telephone you on the third day after the vaccination to check whether you have had any symptoms or concerns since the first check-up on the day after vaccination. Subsequent Visits On every subsequent visit we will ask questions about your health and, if necessary, we will carry out a physical examination. You will have between 25 and 90 ml (roughly 1½ 6 tablespoons) of blood taken at each visit (on average, just under 4 tablespoons per visit) with a total of no more than 670 ml taken over a period of 8 months. 670 ml is less than the amount that would be taken from regular blood donors at a Blood Donation Centre during an 8-month period. What will happen to the blood samples that I give? The blood tests will include a full blood count, blood chemistry and liver function tests at selected visits, to ensure that the vaccines are safe. In addition, a blood sample will be taken at each visit for research laboratory tests that will measure your immune response to HIV-1 and HCV, evidence of other infections, and your Human Leukocyte Antigen (HLA) tissue type (similar to blood group). The HLA typing is the only genetic test which will be performed. Some of each sample will be stored at each visit for future tests. Blood samples will be labelled with your unique study code only, before sending to the appropriate laboratory for analysis or storing for future testing. If you choose to withdraw from the study, any of your anonymised samples collected prior to withdrawal may be used for future tests. Page 4 of 10

5 The chart below gives a summary of what will happen at each visit: Number of visits 12 Duration of study 8 months (238 days) Vaccination visits Day 0 and 56 Blood samples Screening visit, days 0, 1, 7, 14, 28, 56, 57, 63, 84, 98 and 238 Urine sample Screening visit Pregnancy test (if applicable) Screening visit, day 0 and day 56 Physical examination Screening visit, days 0, 7, 28, 56, 63, 84, 98 and 238 What are the risks of taking part? The HIV and Hep C vaccines have each been given to healthy volunteers with no significant or serious side effects. For this reason, we do not expect that giving the HIV and Hep C vaccines together will cause any harm. However, we do not yet know whether there are any particular risks associated with the vaccinations being combined in this study. Risks of vaccination The most common side effects we have seen when the HIV and Hep C vaccines are injected into the shoulder muscle are aching and sometimes redness at the injection site, which can develop over a few days. In addition, tiredness and occasionally flu -like symptoms can develop over 2 days following the injection but these symptoms usually settle without treatment. We do not expect to see any serious adverse reactions when these series of vaccines are given. No serious side effects were observed in people receiving these vaccines individually. However, it is possible that any new combination of vaccines may produce new and unexpected side effects in humans. Any vaccination has the potential to cause the following: Redness, pain, swelling, itching, bruising, a warm feeling Flu-like symptoms such as fever, chills, muscle aches and pains, headaches, nausea, dizziness, fatigue Page 5 of 10

6 Allergic reactions such as an itchy rash, low blood pressure, sudden body swelling, serious breathing difficulty A temporary ache around the injection site For these reasons, we will observe you in the clinic for 30 minutes to 1 hour after vaccination. Risks of taking blood samples (venepuncture) Having blood taken may cause discomfort, bleeding or bruising where the needle enters the body and, in rare cases, light-headedness and fainting. We do not foresee that the amount of blood taken during the study will cause harm to your health. In similar studies we have conducted previously at the University of Oxford, no-one has developed anaemia during this time. However, we will check for anaemia at regular intervals during the study. Incidental findings If at screening or any time during the study a blood sample indicates that you may be positive for HIV or Hep C, we will take a second sample to confirm this result. In the event that this is a true positive result we will discuss the implications with you and refer you for treatment and/or support. False positive results on Hep C or HIV-1 tests As a result of vaccination with Hep C1 or Hep C2 you may test positive for antibodies against Hep C and these antibodies may persist in the future. This is a result of the vaccination and NOT because of Hep C infection. There is a simple blood test which can tell if you have contracted Hep C: this test, called PCR (polymerase chain reaction), is able to detect even small amounts of virus in the blood. Before and after the trial we will do PCR to verify that you are not infected with the Hep C virus. The test can be repeated in the future if you need to reassure yourself that you have not contracted Hep C infection. The presence of antibodies that you might have developed as a result of the vaccination will not alter the result of the PCR test. If you do develop antibodies to the Hep C virus we will, with your permission, write to your GP explaining this and give a copy of the letter to you to keep for the future. The text of the letter will be as follows: The individual named above participated in a trial of an experimental vaccine against Hepatitis C Virus (HCV) conducted at Oxford University. At enrolment the individual was tested for HCV antibodies and also for the presence of the virus by polymerase chain reaction (PCR) analysis. Both these tests were Page 6 of 10

7 negative. Tests for the presence of the virus by PCR at the end of the trial were negative and we can confirm that at this point the individual had not been exposed to HCV and was not a carrier. As a result of the vaccination, this individual has have generated antibodies against HCV proteins, which will result in a positive response in a HCV antibody screening test. This test result should not be taken as a marker of current or previous infection with HCV and has no impact on their health status. They present no risk of transmission of HCV; this status can be confirmed if necessary by analysis of plasma for HCV viral RNA by PCR. However, according to the current regulations of the National Blood Service, HCV antibody positive tests results will exclude the individual from being a blood or tissue donor as long as they remain positive, although it will not necessarily impact upon the ability to be an organ donor." There is a very low chance that vaccination with the HIV vaccines may also cause some HIV-1 tests to give false positive results following vaccination. The chance of a false positive HIV-1 test result is very low because the vaccines contain only fragments of HIV, not entire natural HIV proteins. If this does occur, we will test again using different methods that will be able to distinguish true infection from a result due to vaccination and we will provide an explanatory letter for your personal records and for your GP. Social harms It is possible that by taking part in this study, others may perceive you to be at risk of HIV or Hep C infection or stigmatise you. If you have any concerns or difficulties, trial staff will provide assistance and support. Risks associated with other HIV vaccine candidates in other trials Many clinical trials have tested the safety of other HIV vaccine candidates, but only a few vaccines have been tested in human volunteers to see if the vaccine could protect against HIV infection and/or AIDS. Two of these other vaccines had no effect and one had a very modest protective effect. None of these other vaccines was the same as the vaccines you will receive. A vaccine based on a vector made from a human adenovirus called HAdV-5 (also called Ad5) was tested in two studies (STEP and Phambili) in over 3000 men and women at risk for HIV in the Americas, Australia and South Africa. The HAdV-5 vector is a weakened form of a common cold virus. Vaccinations in both trials were stopped in 2007 because the vaccines did not prevent HIV infections and did not reduce the amount of HIV in the bloodstream of participants who became HIV-infected. In the STEP study, there were more HIV infections in vaccinated men than in the men who received Page 7 of 10

8 placebo. This was an unexpected result, which the trial had not been designed to detect. Men who already had antibody to HAdV-5 at the time of enrolment due to natural exposure to the adenovirus and were not circumcised showed more HIV infections; this was probably not due to chance. When the Phambili trial stopped vaccinations, there were more HIV infections in vaccinated women than in women who received placebo. This difference could have been due to chance, meaning that the vaccine was no different from placebo at protecting from HIV infection, because the trial was stopped very early. A different vaccine, also based on a vector made from HAdV-5, along with a DNA vaccine, has recently been tested in a large trial called HVTN 505 in the United States. This study enrolled about 2500 men who were at risk for HIV infection but did not have antibody to HAdV-5 and who were circumcised. In April 2013, the trial vaccinations were stopped because the vaccine did not protect against HIV infection and did not reduce the amount of HIV in the bloodstream of people became infected. There were slightly more HIV infections in the vaccine group compared to the placebo group. Statisticians determined that a difference of this size could occur by chance alone, meaning that this vaccine was not associated with increased risk of HIV infection. We are testing biologically different adenoviruses from HAdV-5, called AdCh3 and ChAdV63, isolated from chimpanzees. Antibodies to these viruses are very rare in people. Will the study benefit me? You will receive no direct benefit from this study. The aim of the study is to see whether co-vaccination against HIV and Hep C stimulates an immune response against both HIV-1 and Hep C, but you will not be protected against Hep C or HIV-1 infection, or AIDS. However, knowledge gained may in the future help others to avoid HIV-1 or Hep C infection. Can I take part in this study if I am pregnant? If you are trying to or planning to become pregnant, or if you are breast-feeding, you should not take part in this study. The safety of the vaccines in pregnancy is not known. You or your partner will be asked to use an effective method of contraception during the study, if this is appropriate and if you are not already doing so. Contraception will need to be continued for the duration of the study. If you become pregnant during the study, you should tell us immediately. Page 8 of 10

9 Will I be able to participate in other trials in the future if I have received this vaccine? This depends on the specific criteria of each trial and it would need to be discussed on an individual basis. If you decide not to take part or to withdraw from this study because you wish to ensure that you are eligible for another study, we will respect your decision. Will the information from the study be confidential? Yes, all your records will be kept confidential. In addition to the doctors and nurses that you meet, other trial staff involved who have access to your records are equally bound to respect your confidentiality. The data will be collected and kept in accordance with the Data Protection Act All data will be coded, which means that your name will not be used on any research report or samples collected during the study. Your identifiable information will be kept in a secure location separate to the anonymised data for the duration of the study. Authorised members of the University of Oxford may be given access to data for monitoring and/or audit of the study to ensure we are complying with the regulations. Anonymised data collected during the course of the study may be passed onto other organisations, which may include commercial organisations. What if new information becomes available? We will share any new information learned during the course of the study that might change your mind about staying in the study. Who reviews the study? The trial procedures have been reviewed and approved by the Research Ethics Committee (REC). The REC along with an independent committee of experts (Data Safety Monitoring Committee) will monitor the progress of the trial, playing close attention to events that could have an impact on the health of the participants. What happens to the results at the end of the study? One of the study doctors will inform you of the results of the trial. The data gathered from the research will be submitted for publication in scientific journals. In addition, we may produce reports for the general public which would be published via the web and other media. You will not be identified in any report or publication. Who sponsors the study? The study is sponsored by the University of Oxford. Page 9 of 10

10 Research-Related Injury We do not expect you to suffer any injury as a result of participating in this study. Medical care will be organised in the unlikely event that an injury related to the study does occur. The University of Oxford, as Sponsor, has appropriate insurance in place for the unlikely event that you suffer any harm as a direct consequence of your participation in this trial. Will I be paid for taking part in this study? You will receive between 40 to 60 per study visit to compensate you for your time and travel. If you participate in the study until the end, you will receive a total payment of 780. If you choose to leave the study early or are withdrawn from the study you will be compensated according to the length of your participation based on these figures. You should note that compensation payments received in the trial may have an impact on your entitlements to benefits. What happens if I have a complaint? If you wish to complain about any aspect of the way in which you have been approached or treated during the course of this study, you should contact the Chief Investigator, Lucy Dorrell, on Alternatively, you may contact the University of Oxford Clinical Trials and Research Governance (CTRG) office on , or by at ctrg@admin.ox.ac.uk. Who can I contact for more information? For questions about this study please contact: vaccinetrials@ndm.ox.ac.uk, Tel.: Centre of Clinical Vaccinology and Tropical Medicine (CCVTM), Churchill Hospital, Old Road, Headington, Oxford, OX3 7LE If you have any questions you would prefer to discuss with a staff member who is not directly involved in this research, please contact: Dr Brian Angus, Consultant Physician brian.angus@ndm.ox.ac.uk, Tel.: Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU Page 10 of 10

PARTICIPANT INFORMATION SHEET: EBL01

PARTICIPANT INFORMATION SHEET: EBL01 Professor Adrian Hill E-mail: vaccinetrials@ndm.ox.ac.uk Tel: 01865 857406 NRES Committee South Central - Oxford A ref number: 14/SC/1256 Jenner Institute University of Oxford CCVTM, Churchill Hospital,

More information

PARTICIPANT INFORMATION SHEET: EBL04

PARTICIPANT INFORMATION SHEET: EBL04 Professor Adrian Hill E-mail: vaccinetrials@ndm.ox.ac.uk Tel: 01865 857406 INSERT LOCAL DETAILS NRES Committee South Central - Oxford A ref number:15/sc/0108 PARTICIPANT INFORMATION SHEET: EBL04 A study

More information

Be on the TEAM: Teenagers against Meningitis

Be on the TEAM: Teenagers against Meningitis Oxford Vaccine Group University of Oxford Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Headington, Oxford OX3 7LE Tel: 01865 611400 info@ovg.ox.ac.uk www.ovg.ox.ac.uk Be on

More information

PARTICIPANT INFORMATION SHEET. Clinical trial to evaluate a new Hepatitis B vaccine (CONSTANT study)

PARTICIPANT INFORMATION SHEET. Clinical trial to evaluate a new Hepatitis B vaccine (CONSTANT study) Oxford Vaccine Group University of Oxford Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Headington, Oxford OX3 7LE Telephone: 01865 611400 info@ovg.ox.ac.uk www.ovg.ox.ac.uk

More information

Participant Information Leaflet

Participant Information Leaflet Participant Information Leaflet Research: Hand to nose transmission of Streptococcus pneumoniae in healthy participants: randomised control trial assessing the effect of hand Would you like to take part

More information

IRB Approval From: 3/8/2010 To: 10/28/2010

IRB Approval From: 3/8/2010 To: 10/28/2010 UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM Phase II Study to Assess the Safety and Immunogenicity of an Inactivated Swine-Origin H1N1 Influenza Vaccine in HIV-1 (Version 3.0, 16 FEB 2010) IRB Approval From:

More information

PARTICIPANT INFORMATION SHEET: VAC059

PARTICIPANT INFORMATION SHEET: VAC059 Professor Adrian Hill E-mail: vaccinetrials@ndm.ox.ac.uk Tel: 01865 857401 Centre for Clinical Vaccinology and Tropical Medicine (CCVTM) Churchill Hospital Oxford, OX3 7LE Recruitment Co-ordinator Tel:

More information

Study information booklet

Study information booklet Oxford Vaccine Group University of Oxford Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Headington, Oxford OX3 7LE Telephone: 01865 611400 info@ovg.ox.ac.uk www.ovg.ox.ac.uk

More information

FLIPS FreeStyle Libre in Pregnancy Study

FLIPS FreeStyle Libre in Pregnancy Study FLIPS FreeStyle Libre in Pregnancy Study Evaluation of the Accuracy of the FreeStyle Libre Flash Glucose Monitoring System Use in Pregnancy Label Extension Study (CE) Section 1: PARTICIPANT INFORMATION

More information

Patient Information Sheet

Patient Information Sheet Research Trial of Treatments for Patients with Bony Metastatic Cancer of the Prostate. - TRAPEZE Patient Information Sheet Your doctor has explained to you that your prostate cancer is no longer responding

More information

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM White Blood Cell Collection by Leukapheresis in HIV-infected Individuals On Chemotherapy and Controls Not on Chemotherapy: A Study of HIV Reservoir Eradication CONSENT TO PARTICIPATE IN A RESEARCH STUDY

More information

OXFORD VACCINE GROUP

OXFORD VACCINE GROUP OXFORD VACCINE GROUP ADITEC FLU 2 STUDY: Understanding the genetic basis for immune responses to flu vaccines in children and adults Information Booklet (Child and Parent) We would like to invite your

More information

The Johns Hopkins Bloomberg School of Public Health

The Johns Hopkins Bloomberg School of Public Health The Johns Hopkins Bloomberg School of Public Health CONSENT FORM A / NEW RESEARCH PROJECT Title of Research Project: A Randomized Trial of HAART in Acute/Early HIV Infection Version 3.0 Principal Investigator:

More information

Bristol Children s Vaccine Centre

Bristol Children s Vaccine Centre Bristol Children s Vaccine Centre Bristol Children s Vaccine Centre Level 6, UHB Education Centre, Upper Maudlin St., Bristol, BS2 8AE, UK Tel: +44 (0)117 342 0172, Fax: +44 (0)117 342 0209 E-mail: bcvc-study@bristol.ac.uk,

More information

Suspected CANcer (SCAN) Pathway Information for patients

Suspected CANcer (SCAN) Pathway Information for patients Suspected CANcer (SCAN) Pathway Information for patients page 2 Your GP has advised you may benefit from investigation via the SCAN pathway. The SCAN pathway is part of a national programme called ACE

More information

IMPORTANT: PLEASE READ

IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION combined hepatitis A (inactivated) and hepatitis B (recombinant) vaccine This leaflet is part III of a three-part "Product Monograph" published when was approved for sale

More information

UNIVERSITY OF PENNSYLVANIA RESEARCH SUBJECT INFORMED CONSENT AND HIPAA AUTHORIZATION FORM

UNIVERSITY OF PENNSYLVANIA RESEARCH SUBJECT INFORMED CONSENT AND HIPAA AUTHORIZATION FORM UNIVERSITY OF PENNSYLVANIA RESEARCH SUBJECT INFORMED CONSENT AND HIPAA AUTHORIZATION FORM Protocol Title: Principal Investigator: 24 hr. Emergency Contact: Evaluating the HIV-1 Reservoir: BEAT HIV Delaney

More information

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM Gilead Sciences, Inc. GS-US-337-0115, 25-NOV-2013 A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects

More information

PARTICIPANT INFORMATION SHEET: VAC063 (Groups 5 & 6) A study to assess the new malaria vaccines RH5.1/AS01

PARTICIPANT INFORMATION SHEET: VAC063 (Groups 5 & 6) A study to assess the new malaria vaccines RH5.1/AS01 Dr Angela M. Minassian E-mail: vaccinetrials@ndm.ox.ac.uk Tel: +44 1865 611406 (volunteer co-ordinator) IRAS project ID: 206835 NRES Committee South Central - Oxford A Reference number: 16/SC/0345 VAC063:

More information

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM. A Pilot Study for Collection of Anti-Zika Immune Plasma

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM. A Pilot Study for Collection of Anti-Zika Immune Plasma A Pilot Study for Collection of Anti-Zika Immune Plasma CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION Your contacts for this study at the Hospital of the University

More information

INFORMATION AND CONSENT FORM For Adults Aged 18 and Older Additional Facility Sites

INFORMATION AND CONSENT FORM For Adults Aged 18 and Older Additional Facility Sites INFORMATION AND CONSENT FORM Program Title: Expanded Access IND Program to Provide Stamaril Vaccine to Persons in the United States for Vaccination Against Yellow Fever Program #: Sponsor: Sanofi Pasteur

More information

PATIENT STUDY INFORMATION LEAFLET

PATIENT STUDY INFORMATION LEAFLET PATIENT STUDY INFORMATION LEAFLET BOOKLET 1 You are invited to take part in this research study. Before you decide, it is important for you to understand why the research is being done and what it will

More information

Adult Patient Information and Consent Form

Adult Patient Information and Consent Form The ROAM Trial Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial

More information

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM IRC 002, Version 5.0, 20 AUG 2012: A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational anti-influenza A Immune Plasma for the Treatment of Influenza

More information

For Parents and Students: Minor Donor Permit and Information About Donating Blood

For Parents and Students: Minor Donor Permit and Information About Donating Blood DIN NUMBER 102 Chestnut Ridge Road, Montvale NJ 07645 DID For Parents and Students: Minor Donor Permit and Information About Donating Blood Every day people like you need blood: students, teachers, family,

More information

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO PARTICIPATE IN A RESEARCH STUDY

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO PARTICIPATE IN A RESEARCH STUDY UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO PARTICIPATE IN A RESEARCH STUDY Study Title: Assessment of Biochemical Pathways and Biomarker Discovery in Autism Spectrum Disorder This is a research

More information

PrEP Impact Trial: A Pragmatic Health Technology Assessment of PrEP and Implementation. Part 1

PrEP Impact Trial: A Pragmatic Health Technology Assessment of PrEP and Implementation. Part 1 The Elton John Centre Sussex House 1 Abbey Road Brighton BN2 1ES Tel 01273 523079 Fax 01273 523080 PARTICIPANT INFORMATION SHEET AND CONSENT FORM PrEP Impact Trial: A Pragmatic Health Technology Assessment

More information

A study of Standard and New Antiepileptic Drugs SANAD-II

A study of Standard and New Antiepileptic Drugs SANAD-II The SANAD II project is funded by the NIHR Health Technology Assessment Programme. Hospital Logo Address NIHR code A study of Standard and New Antiepileptic Drugs SANAD-II ADULT INFORMATION SHEET www.sanad2.org.uk

More information

Department of Health. Year 8. vaccination program. Important information for parents and students

Department of Health. Year 8. vaccination program. Important information for parents and students Department of Health Year 8 vaccination program Important information for parents and students Contents Why immunise? 1 Vaccination program 1 Schedule of vaccinations 2 Vaccination records 2 Vaccine safety

More information

Pregnant? There are many ways to help protect you and your baby. Immunise against: Flu (Influenza) Whooping cough (Pertussis) German measles (Rubella)

Pregnant? There are many ways to help protect you and your baby. Immunise against: Flu (Influenza) Whooping cough (Pertussis) German measles (Rubella) Pregnant? There are many ways to help protect you and your baby Immunise against: Flu (Influenza) Whooping cough (Pertussis) German measles (Rubella) mmunisation This leaflet describes the vaccinations

More information

PATIENT STUDY INFORMATION LEAFLET

PATIENT STUDY INFORMATION LEAFLET PATIENT STUDY INFORMATION LEAFLET BOOKLET 1 You are invited to take part in this research study. Before you decide, it is important for you to understand why the research is being done and what it will

More information

CONSUMER MEDICINE INFORMATION (CMI) OCTAGAM 10% [100 mg/ml]

CONSUMER MEDICINE INFORMATION (CMI) OCTAGAM 10% [100 mg/ml] CONSUMER MEDICINE INFORMATION (CMI) OCTAGAM 10% [100 mg/ml] Human Normal Immunoglobulin Solution for Intravenous Infusion. OCTAGAM 10% [100 mg/ml] is available in single use bottles of 20 ml, 50 ml, 100

More information

Patient Information Sheet. PSC Cohort

Patient Information Sheet. PSC Cohort Analysis of liver infiltrating lymphocytes in primary sclerosing cholangitis by fine needle aspiration of the liver. Patient Information Sheet PSC Cohort Chief Investigator: Dr Kate Williamson Investigators:

More information

Help keep hepatitis A and B out of your travel plans.

Help keep hepatitis A and B out of your travel plans. Help keep hepatitis A and B out of your travel plans. Hepatitis A and B: Facts for Canadian travellers. Many common travel activities may put travellers at risk for hepatitis A and B. Hepatitis A and B

More information

D-Gam 250 micrograms/ml. Solution for injection. human anti-d immunoglobulin

D-Gam 250 micrograms/ml. Solution for injection. human anti-d immunoglobulin Package leaflet: Information for the patient D-Gam 50 micrograms/ml D-Gam 250 micrograms/ml Solution for injection human anti-d immunoglobulin Read all of this leaflet carefully before you start using

More information

Influvac Inactivated influenza vaccine [surface antigen]

Influvac Inactivated influenza vaccine [surface antigen] Influvac Inactivated influenza vaccine [surface antigen] Consumer Medicine Information WHAT IS IN THIS LEAFLET This leaflet answers some of the common questions about Influvac vaccine. It does not contain

More information

Ustekinumab is used to treat moderate to severe plaque psoriasis in adults. Why have I been selected for treatment with ustekinumab?

Ustekinumab is used to treat moderate to severe plaque psoriasis in adults. Why have I been selected for treatment with ustekinumab? USTEKINUMAB What are the aims of this leaflet? This leaflet has been written to help you understand more about ustekinumab (Stelara TM ). It tells you what it is, how it works, how it is used to treat

More information

Patient information leaflet. A study of low dose theophylline in Chronic Obstructive Pulmonary Disease (COPD)

Patient information leaflet. A study of low dose theophylline in Chronic Obstructive Pulmonary Disease (COPD) Patient information leaflet A study of low dose theophylline in Chronic Obstructive Pulmonary Disease (COPD) Theophylline With Inhaled CorticoSteroids (TWICS) study. We would like to invite you to take

More information

GARDASIL 9 [Human Papillomavirus 9-valent Vaccine, Recombinant] Consumer Medicine Information

GARDASIL 9 [Human Papillomavirus 9-valent Vaccine, Recombinant] Consumer Medicine Information GARDASIL 9 [Human Papillomavirus 9-valent Vaccine, Recombinant] Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about It does not contain all the available

More information

Some general information on hepatitis A infection is given at the end of this leaflet.

Some general information on hepatitis A infection is given at the end of this leaflet. Package Leaflet: Information for the User Havrix Monodose Vaccine Suspension for injection in a pre-filled syringe Hepatitis A (inactivated) vaccine (adsorbed) Read all of this leaflet carefully before

More information

Couples Information Leaflet

Couples Information Leaflet Couples Information Leaflet This project was funded by the National Institute for Health Research, Health Technology Assessment Programme (project number 13/115/82) You are due to undergo in vitro fertilisation

More information

INFORMATION AND CONSENT FORM

INFORMATION AND CONSENT FORM INFORMATION AND CONSENT FORM A RANDOMIZED CONTROLLED TRIAL TO COMPARE THE IMMUNOGENICITY OF SELF- ADMINISTERED AND NURSE-ADMINISTERED INTRADERMAL INFLUENZA VACCINE Investigators Dr. Shelly McNeil Queen

More information

Why have I been selected for treatment with adalimumab?

Why have I been selected for treatment with adalimumab? ADALIMUMAB What are the aims of this leaflet? This leaflet has been written to help you understand more about adalimumab (Humira TM ). It tells you what it is, how it works, how it is used to treat skin

More information

Study Plan: Screening

Study Plan: Screening Phase 1 with Sporozoite Challenge Open-Label Dose-Escalation Safety, Reactogenicity, Immunogenicity, and Efficacy of the Vaccine Candidate Plasmodium falciparum Malaria Protein (FMP012), an E coli-expressed

More information

To: Parents & Guardians of Students in Franklin County Schools

To: Parents & Guardians of Students in Franklin County Schools Florida Department of Health in Franklin County School Health Program To: Parents & Guardians of Students in Franklin County Schools Date: 10/1/18 RE: 2018/2019 Influenza Vaccine (Flu shots) This year,

More information

Methotrexate for inflammatory bowel disease: what you need to know

Methotrexate for inflammatory bowel disease: what you need to know Methotrexate for inflammatory bowel disease: what you need to know This leaflet aims to answer your questions about taking methotrexate for inflammatory bowel disease (IBD). If you have any questions or

More information

Important safety information to minimise the risk of immune-related adverse reactions

Important safety information to minimise the risk of immune-related adverse reactions Your Guide to KEYTRUDA (pembrolizumab) Important safety information to minimise the risk of immune-related adverse reactions Information for Patients This medicine is subject to additional monitoring.

More information

HREC/17/RCHM/334 RCH HREC 37278A. ANZ CLARITY Establishment of a National Juvenile Idiopathic Arthritis Biobank.

HREC/17/RCHM/334 RCH HREC 37278A. ANZ CLARITY Establishment of a National Juvenile Idiopathic Arthritis Biobank. HREC Project Number: Research Project Title: Principal Researchers: HREC/17/RCHM/334 RCH HREC 37278A ANZ CLARITY Establishment of a National Juvenile Idiopathic Arthritis Biobank. Associate Professor Justine

More information

VERBAL CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND HIPPA AUTHORIZATION

VERBAL CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND HIPPA AUTHORIZATION VERBAL CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND HIPPA AUTHORIZATION Study Title: Cytokine Production and Lymphoproliferation With and Without Co-inhibitory Signaling Blockade: An Assessment of Functional

More information

Making Your Blood Donation Safe

Making Your Blood Donation Safe BLOOD DONOR EDUCATIONAL MATERIALS Making Your Blood Donation Safe Pete Lawson Burned in a wildfire, LifeStream blood donations saved his life. WWW.LSTREAM.ORG NEW! Important Information on Iron! Recent

More information

HAVRIX 1440 and HAVRIX Junior

HAVRIX 1440 and HAVRIX Junior HAVRIX 1440 and HAVRIX Junior Inactivated Hepatitis A Virus Vaccine Consumer Medicine Information Leaflet In this leaflet, HAVRIX refers to the use of both HAVRIX 1440 for adults and HAVRIX Junior for

More information

VIVAXIM Salmonella typhi Vi polysaccharide and inactivated hepatitis A virus antigen vaccine

VIVAXIM Salmonella typhi Vi polysaccharide and inactivated hepatitis A virus antigen vaccine VIVAXIM Salmonella typhi Vi polysaccharide and inactivated hepatitis A virus antigen vaccine Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about VIVAXIM.

More information

Thank you for scheduling your influenza immunization clinic with Bloomington Public Health. We have your clinic(s) scheduled for:

Thank you for scheduling your influenza immunization clinic with Bloomington Public Health. We have your clinic(s) scheduled for: Thank you for scheduling your influenza immunization clinic with Bloomington Public Health. We have your clinic(s) scheduled for: Southpoint Office Center Wednesday, 10/4/2017 10:00 am 1:00 pm Please let

More information

Life After Prostate Cancer Diagnosis Research Study

Life After Prostate Cancer Diagnosis Research Study Life After Prostate Cancer Diagnosis Research Study If you are looking at this information sheet this means you have read the covering letter and therefore have had a diagnosis of prostate cancer. If you

More information

Rituximab treatment in autoimmune blistering diseases

Rituximab treatment in autoimmune blistering diseases Rituximab treatment in autoimmune blistering diseases This leaflet explains more about having treatment with the medicine rituximab for an autoimmune blistering disease. It includes information about the

More information

Traztuzumab (Herceptin)

Traztuzumab (Herceptin) Traztuzumab (Herceptin) Information for patients Chemotherapy Name Hospital No Your consultant is Important Advice Always carry your chemotherapy alert card. It is important that you know what to do if

More information

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM IRC 004, Version 5, July 31, 2013 A Randomized Double-Blind Study Comparing Oseltamivir versus Placebo for the Treatment of Influenza in Low Risk Adults CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH

More information

UK Teratology Information Service Regional Drug & Therapeutics Centre Wolfson Unit Newcastle upon Tyne NE2 4HH PARTICIPANT INFORMATION SHEET

UK Teratology Information Service Regional Drug & Therapeutics Centre Wolfson Unit Newcastle upon Tyne NE2 4HH PARTICIPANT INFORMATION SHEET UK Teratology Information Service Regional Drug & Therapeutics Centre Wolfson Unit Newcastle upon Tyne NE2 4HH Tel: 0191 260 6197 Fax: 0191 260 6193 www.uktis.org PARTICIPANT INFORMATION SHEET Influenza

More information

Immunisation for pre-school children. three years and four months old

Immunisation for pre-school children. three years and four months old Immunisation for pre-school children three years and four months old Introduction This leaflet contains the facts about the diphtheria, tetanus, pertussis and polio booster vaccine, and the second MMR

More information

NeisVac-C Meningococcal group C polysaccharide conjugate vaccine (tetanus toxoid protein conjugate)

NeisVac-C Meningococcal group C polysaccharide conjugate vaccine (tetanus toxoid protein conjugate) NeisVac-C Meningococcal group C polysaccharide conjugate vaccine (tetanus toxoid protein conjugate) Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about

More information

We ll be our own lifesavers. We ll get the flu vaccine.

We ll be our own lifesavers. We ll get the flu vaccine. We ll be our own lifesavers. We ll get the flu vaccine. The flu vaccine is a lifesaver for older people and those with long-term health conditions. www.immunisation.ie Flu Vaccine 2017-18 What is seasonal

More information

PATIENT INFORMATION SHEET

PATIENT INFORMATION SHEET PATIENT INFORMATION SHEET Optimal management of Rheumatoid Arthritis patients who require Biologic Therapy (ORBIT study) a randomized controlled trial comparing Rituximab and anti-tnf therapy. Invitation

More information

CONSENT TO BE A RESEARCH PARTICIPANT Version of the Informed Consent DAIDS-ES Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients

CONSENT TO BE A RESEARCH PARTICIPANT Version of the Informed Consent DAIDS-ES Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients CONSENT TO BE A RESEARCH PARTICIPANT Version of the Informed Consent DAIDS-ES 20730 Impact of CCR5 Blockade in CONSENT VERSION 3.0 /October 2, 2017 PROTOCOL VERSION 3.0 /October 2, 2017 [NOTE: Site specific

More information

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM CONSENT TO PARTICIPATE IN A LONG TERM FOLLOW UP TO A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM CONSENT TO PARTICIPATE IN A LONG TERM FOLLOW UP TO A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM CONSENT TO PARTICIPATE IN A LONG TERM FOLLOW UP TO A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION Protocol No. VRX496-USA-11-001-LTFU: Long-term Follow-up

More information

BCHOOSE TO VACCINATED. Ask your doctor about the MenB * vaccine.

BCHOOSE TO VACCINATED. Ask your doctor about the MenB * vaccine. BCHOOSE TO VACCINATED Vaccinate against meningococcal disease caused by Neisseria meningitidis group B strains (MenB) with BEXSERO BEXSERO multicomponent meningococcal B vaccine (recombinant, adsorbed)

More information

PATIENT AUTHORIZATION AND NOTICE OF RELEASE OF INFORMATION (PAN)

PATIENT AUTHORIZATION AND NOTICE OF RELEASE OF INFORMATION (PAN) XOLAIR Access Solutions is a free program for you from Genentech. We work to help you pay for your XOLAIR (omalizumab) for subcutaneous use. We can help in many different ways. We assist people who have

More information

PATIENT INFORMATION BOOKLET

PATIENT INFORMATION BOOKLET PATIENT INFORMATION BOOKLET GETTING STARTED WITH YOUR MEDICINES TIVICAY (dolutegravir) + lamivudine Tivicay is subject to additional monitoring. This will allow quick identification of new safety information.

More information

IMOJEV Japanese encephalitis vaccine (live, attenuated)

IMOJEV Japanese encephalitis vaccine (live, attenuated) IMOJEV Japanese encephalitis vaccine (live, attenuated) Consumer Medicine Information What is in this leaflet Read all of this leaflet carefully before you or your child is vaccinated. Keep this leaflet.

More information

TYPHIM Vi, Solution for injection

TYPHIM Vi, Solution for injection PACKAGE LEAFLET: INFORMATION FOR THE USER TYPHIM Vi, Solution for injection Purified Vi Capsular Polysaccharide of Salmonella typhi (Ty 2 Strain). Read all of this leaflet carefully before you are vaccinated

More information

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM. A5272 Version 2.0, 5/19/11: Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM. A5272 Version 2.0, 5/19/11: Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy A5272 Version 2.0, 5/19/11: Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION Your contacts

More information

Plasma-derived products Information for patients

Plasma-derived products Information for patients Plasma-derived products Information for patients page 2 You have been given this leaflet as your doctor has advised you that you may require plasma-derived products as a treatment for your bleeding disorder.

More information

Your guide to the HPV vaccine

Your guide to the HPV vaccine Your guide to the HPV vaccine This leaflet gives you information about the human papillomavirus (HPV) vaccine offered to all girls in school year 8 to protect against cervical cancer. This leaflet explains

More information

Peripheral Blood Stem Cell Collection for Lymphoma Patients

Peripheral Blood Stem Cell Collection for Lymphoma Patients Department of Clinical Haematology Peripheral Blood Stem Cell Collection for Lymphoma Patients Information for patients PI.37 March 2016 V.4.0 PBSC for Lymphoma patients You may find this booklet helpful

More information

All medicines have risks and benefits. Your doctor has weighed the risks of you being given Mabthera SC against the benefits expected for you.

All medicines have risks and benefits. Your doctor has weighed the risks of you being given Mabthera SC against the benefits expected for you. New Zealand Consumer Medicine Information MABTHERA SC Rituximab 1400 mg solution for subcutaneous injection for non-hodgkin s Lymphoma and 1600mg solution for subcutaneous injection for chronic lymphocytic

More information

Privigen solution for infusion

Privigen solution for infusion Privigen solution for infusion Haematology Patient Information What is is Privigen? Privigen? Privigen belongs in a class of medicines called human normal immunoglobins. Immunoglobulins are also called

More information

MERIEUX INACTIVATED RABIES VACCINE (MIRV) Rabies Vaccine

MERIEUX INACTIVATED RABIES VACCINE (MIRV) Rabies Vaccine MERIEUX INACTIVATED RABIES VACCINE (MIRV) Rabies Vaccine Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Merieux Inactivated Rabies Vaccine (MIRV).

More information

ACT-HIB powder and solvent for solution for injection Haemophilus influenzae type b Conjugate Vaccine

ACT-HIB powder and solvent for solution for injection Haemophilus influenzae type b Conjugate Vaccine 1 PATIENT INFORMATION LEAFLET ACT-HIB powder and solvent for solution for injection Haemophilus influenzae type b Conjugate Vaccine Read all of this leaflet carefully before your child is vaccinated. Keep

More information

FLU VACCINE INFORMATION SHEET

FLU VACCINE INFORMATION SHEET FLU VACCINE INFORMATION SHEET WHAT IS INFLUENZA? HOW IS INFLUENZA TRANSMITTED? WHY DO I NEED A FLU SHOT ANNUALLY? CAN I GET THE FLU FROM THE FLU SHOT? WHO SHOULD RECEIVE THE FLU SHOT? WHO SHOULD NOT RECEIVE

More information

FLU Clinic. Children 6 months through 18 years October 26 th, p.m. to 6 p.m. At the Milbank High School Lobby

FLU Clinic. Children 6 months through 18 years October 26 th, p.m. to 6 p.m. At the Milbank High School Lobby FLU Clinic Children 6 months through 18 years October 26 th, 2016 2 p.m. to 6 p.m. At the Milbank High School Lobby MUST BRING: Insurance/Medicaid Cards All others please inquire. INFLUENZA 2016-2017 INACTIVATED

More information

Pemetrexed APOTEX Powder for Injection Contains the active ingredient pemetrexed (as disodium)

Pemetrexed APOTEX Powder for Injection Contains the active ingredient pemetrexed (as disodium) Pemetrexed APOTEX Powder for Injection Contains the active ingredient pemetrexed (as disodium) Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 195 055 What is in this leaflet

More information

Maternity Services Intravenous iron therapy Information for women

Maternity Services Intravenous iron therapy Information for women Maternity Services Intravenous iron therapy Information for women Please read this leaflet carefully. It has been written to give you information about your treatment with intravenous iron therapy. What

More information

If you have any concerns about ENGERIX-B talk to your doctor, nurse or pharmacist.

If you have any concerns about ENGERIX-B talk to your doctor, nurse or pharmacist. ENGERIX-B Recombinant DNA hepatitis B vaccine Consumer Medicine Information Leaflet What Is In This Leaflet? This leaflet answers some of the common questions about ENGERIX-B vaccine. It does not contain

More information

INFORMATION BROCHURE - ALLOCATE

INFORMATION BROCHURE - ALLOCATE INFORMATION BROCHURE - ALLOCATE AustraLian Ovarian Cancer Assortment Trial Principal Investigator: Prof Michael Quinn, Royal Women s Hospital This Participant Information Sheet and Consent Form is 7 pages

More information

Beating cervical cancer

Beating cervical cancer Beating cervical cancer The HPV vaccine questions and answers for parents of girls in Year 9 and 10 This Q&A on the HPV vaccine supports the leaflet that your daughter should have been given at school.

More information

Havrix Monodose Vaccine Hepatitis A Vaccine (Inactivated, adsorbed) ELISA Units/1 ml Suspension for Injection in a pre-filled syringe

Havrix Monodose Vaccine Hepatitis A Vaccine (Inactivated, adsorbed) ELISA Units/1 ml Suspension for Injection in a pre-filled syringe GSK (logo) Package Leaflet: Information for the User Havrix Monodose Vaccine Hepatitis A Vaccine (Inactivated, adsorbed). 1440 ELISA Units/1 ml Suspension for Injection in a pre-filled syringe Read all

More information

TREATMENT OF RECENTLY ACQUIRED HEPATITIS C VIRUS INFECTION (ATAHC II)

TREATMENT OF RECENTLY ACQUIRED HEPATITIS C VIRUS INFECTION (ATAHC II) TREATMENT OF RECENTLY ACQUIRED HEPATITIS C VIRUS INFECTION (ATAHC II) A national study to find the best treatment strategy for people with recently acquired hepatitis C infection. introduction This information

More information

ADACEL POLIO. This leaflet answers some common questions about ADACEL POLIO. It does not take the place of talking to your doctor or pharmacist.

ADACEL POLIO. This leaflet answers some common questions about ADACEL POLIO. It does not take the place of talking to your doctor or pharmacist. ADACEL POLIO Pertussis Vaccine Acellular and Diphtheria and Tetanus Toxoids (Adsorbed) Combined with Inactivated Poliovirus Type 1,2 and 3 (Vero cell) Consumer Medicine Information What is in this leaflet

More information

Information Sheet for Stage 1 Screening for parents

Information Sheet for Stage 1 Screening for parents Chief Investigator Prof. Polly Bingley Diabetes & Metabolism Southmead Hospital Bristol BS10 5NB BETA CELL FUNCTION AND ONGOING AUTOIMMUNITY IN LONG STANDING TYPE 1 DIABETES Information Sheet for Stage

More information

Informed Consent Flipchart. Version 1.0, 30 Jan 2018

Informed Consent Flipchart. Version 1.0, 30 Jan 2018 Informed Consent Flipchart Version 1.0, 30 Jan 2018 Knowledge is Power Did you know? Across the world, young women are at high risk of getting HIV. In Africa, more than half of people living with HIV are

More information

OXFORD VACCINE GROUP

OXFORD VACCINE GROUP Oxford Vaccine Group University of Oxford Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Headington, Oxford OX3 7LE Tel/Fax: 01865 611400/289695 info@ovg.ox.ac.uk www.ovg.ox.ac.uk

More information

A study about how parts of the brain work in people with Down syndrome

A study about how parts of the brain work in people with Down syndrome A study about how parts of the brain work in people with Down syndrome Our names are Carla Startin, Sarah Hamburg and Ros Hithersay. We are researchers working at University College London. We are carrying

More information

A Patient s Guide to Blood Components and Products

A Patient s Guide to Blood Components and Products 2014 A Patient s Guide to Blood Components and Products Contents What is a blood transfusion?... 1 Informed consent... 1 Frequently asked questions about blood transfusions... 2 What can I expect during

More information

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO PARTICIPATE IN A RESEARCH STUDY

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO PARTICIPATE IN A RESEARCH STUDY UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO PARTICIPATE IN A RESEARCH STUDY Epileptic Encephalopathies: Clinical and Genetic Predictors of Outcomes and Therapeutic Insights This is a research study.

More information

VANISH Vasopressin vs Noradrenaline as Initial therapy in Septic shock

VANISH Vasopressin vs Noradrenaline as Initial therapy in Septic shock Investigator: Maurizio Cecconi Patient Information Sheet You are being invited to take part in a research study. Before you decide it is important for you to understand why the research is being done and

More information

PATIENT INFORMATION SHEET (Sheffield and Southampton Only)

PATIENT INFORMATION SHEET (Sheffield and Southampton Only) PATIENT INFORMATION SHEET (Sheffield and Southampton Only) ENDOMETRIAL SCRATCH TRIAL A Multicentre Randomised Controlled Trial of Induced Endometrial Scratch in Women Undergoing First Time in Vitro Fertilisation

More information

Red blood cell transfusion

Red blood cell transfusion Red blood cell transfusion This leaflet explains more about red blood cell transfusion, including the benefits, risks and any alternatives and what you can expect when you come to hospital. If you have

More information

PARTICIPANT INFORMATION SHEET Version 2 09/ IRAS Ref No.:

PARTICIPANT INFORMATION SHEET Version 2 09/ IRAS Ref No.: Mechanisms of chronic pain and fatigue PARTICIPANT INFORMATION SHEET Version 2 09/06 2017 IRAS Ref No.: 207362 We would like to invite you to take part in a research study exploring mechanisms of chronic

More information

Questions and answers: HVTN 084 vaccine trial

Questions and answers: HVTN 084 vaccine trial 1. What is the HVTN 084 trial? Questions and answers: HVTN 084 vaccine trial Version 2 Last updated December 2, 2010 HVTN 084 is the name of a clinical trial to test the safety of 2 experimental HIV vaccines.

More information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR VACCINE PART III: PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR VACCINE PART III: PATIENT MEDICATION INFORMATION READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR VACCINE PART III: PATIENT MEDICATION INFORMATION SHINGRIX Herpes Zoster vaccine (non-live recombinant, AS01B adjuvanted) Suspension for Injection Read this

More information